Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CVM vs CRIS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CVM Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–1 Matrix Metrics)
CVM Overall Winner
6-Pillar Tally: CVM 3 – 2 CRIS (1 Tie)
Matrix Metrics: CVM 8 – 1 CRIS
As of Nov 16, 2026, Cel-Sci Corporation (CVM) is the stronger overall head-to-head candidate over Curis Inc (CRIS) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CVM carries a Unified Composite Score of 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin), whereas CRIS carries 38.7/100 (SELL) at $0.44 (N/M Forward P/E, -833.4% operating margin).
- Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 57.1); meanwhile CRIS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CVM vs CRIS
CVM
Head-to-Head Winner
Cel-Sci Corporation
$1.59
+24.22% 1D
Market Cap
$20.9M
TTM Revenue
$28,558
Forward P/E
23.0x
Beta / 30D Vol
0.65β · 120% Vol
Unified Composite Score
56.6
HOLD
Tech 60.0
Fund 54.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
CRIS
Curis Inc
$0.44
-1.07% 1D
Market Cap
$3.8M
TTM Revenue
$4.3M
Forward P/E
N/M
Beta / 30D Vol
11.40β · 269% Vol
Unified Composite Score
38.7
SELL
Tech 15.0
Fund 41.0
Flow 50.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (CVM 3 – 2 CRIS)
1. Valuation Multiples
CVM
Forward P/E
23.0x
N/M
Trailing P/E
23.0x
0.4x
PEG Ratio
1.12x
N/M
EV / Revenue
N/M
N/M
2. Growth & Scale
CVM
Revenue Growth (YoY)
-62.7%
-66.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$28,558
$4.3M
Market Cap
$20.9M
$3.8M
3. Profitability & Quality
CVM
Gross Margin
N/A
N/A
Operating Margin
0.0%
-833.4%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-252.5%
-693.9%
4. Balance Sheet & Cash Flow
CRIS
Cash Generation (TTM)
-$17M
-$36M EBITDA
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$6.6M Net Debt (1.24x D/E)
$4.0M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
CRIS
Options Structure Phase
BREAKDOWN
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CVM (8) vs CRIS (1)| Institutional Metric | CVM | CRIS | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $20.9M | $3.8M | CVM | |
| Trailing P/E Ratio | 23.0x | 0.4x | CRIS | |
| Forward P/E Ratio | 23.0x | N/M | CVM | |
| Revenue Growth (YoY) | -62.7% | -66.0% | CVM | |
| Operating Margin (TTM) | 0.0% | -833.4% | CVM | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -252.5% | -693.9% | CVM | |
| 52-Week Range Position | 10% ($1–$8) | 4% ($0–$7) | CVM | |
| Beta / 30D Volatility | 0.65β · 120% Vol | 11.40β · 269% Vol | CVM | |
| Unified Institutional Score | 56.6 / 100 (HOLD) | 38.7 / 100 (SELL) | CVM | |
| Trailing 12M Revenue (USD) | $28,558 | $4.3M | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | 1.12x PEG · N/M EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$17M ($6.6M Net Debt (1.24x D/E)) | -$36M EBITDA ($4.0M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CRIS +19.3 pp
3M Horizon
CVM +74.11 pp
6M Horizon
CVM +0.73 pp
1Y Horizon
CRIS +9.08 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CVM Revenue | CRIS Revenue | CVM Op. Margin | CRIS Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $10M | N/A | -281.3% | CRIS |
| FY2019 | N/A | $10M | N/A | -243.5% | CRIS |
| FY2020 | N/A | $10M | N/A | -229.8% | CRIS |
| FY2021 | N/A | $10M | N/A | -395.0% | CRIS |
| FY2022 | N/A | $10M | N/A | -521.7% | CRIS |
| FY2023 | N/A | $10M | N/A | -482.2% | CRIS |
| FY2024 | N/A | $10M | N/A | -408.3% | CRIS |
| FY2025 | N/A | $10M | N/A | -60.5% | CRIS |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CVM
BREAKDOWN
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CRIS
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact CRIS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CVM Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
CRIS Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ CVM vs CRIS Key Questions & Quantitative Answers
As of Nov 16, 2026, Cel-Sci Corporation (CVM) is the stronger overall head-to-head candidate over Curis Inc (CRIS) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CVM carries a Unified Composite Score of 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin), whereas CRIS carries 38.7/100 (SELL) at $0.44 (N/M Forward P/E, -833.4% operating margin). Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 57.1); meanwhile CRIS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CVM leads the Growth & Scale pillar: CVM posts -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin), compared with CRIS at -66.0% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (N/A gross margin, -833.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CVM cumulative revenue shifted N/A while CRIS shifted +0.0%. In operating R&D and SG&A reinvestment, CVM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CRIS.
CVM screens cheaper on headline valuation multiples. CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin), whereas CRIS trades at N/M Forward P/E, 0.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CVM (-252.5% ROE) versus CRIS (-693.9% ROE) capital efficiency.
In options market volatility and institutional positioning, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.65β · 120% Vol realized risk). By comparison, CRIS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (11.40β · 269% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CRIS vs CVM · Reverse Pair
CVM vs AGEN
· Sector Peer
CVM vs BCRX
· Sector Peer
CRIS vs AGEN
· Sector Peer
CRIS vs RIGL
· Sector Peer
CRIS vs CLDX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem